The Calmer Co (ASX: CCO) has achieved a significant milestone with its highest monthly revenue ever recorded, delivering unaudited December 2025 sales of $910,767. The result represents a breakthrough moment for the kava-focused consumer goods company, driven by accelerating demand across all sales channels including Australian retail, USA Amazon, and B2B ingredient sales.
The Calmer Co December Sales Record reflects both operational excellence and validation of the company’s vertically-integrated farm-to-shelf strategy. The wholesale channel delivered its strongest monthly performance at $340,131, with year-to-date wholesale sales already exceeding total FY25 annual wholesale revenue in the first half of FY26.
Calmer Co Delivers Record $910k Monthly Revenue in Historic December Performance
The Calmer Co (ASX: CCO) has reported its strongest single-month performance since listing, with December 2025 revenue reaching $910,767. This milestone represents a material inflection point demonstrating the company’s transition from growth investment phase to commercial scale.
The record result was underpinned by three primary revenue drivers. Australian retail performance remained robust, led by Fiji Kava® distribution through major grocery chains Coles and Woolworths. USA sales growth accelerated through an expanding Amazon product range including tinctures, capsules, and flavoured kava shots. B2B ingredient sales contributed significantly, supported by increasing global demand for high-kavalactone kava extracts.
“Achieving our highest ever monthly revenue of $910,767 is a defining milestone for The Calmer Co. The wholesale channel’s record performance of $340,131 in a single month, with year-to-date sales already exceeding FY25 annual results, clearly demonstrates the accelerating global demand for high-quality, traceable kava ingredients,” said Zane Yoshida, Founder and CEO.
The wholesale channel’s exceptional performance is particularly significant for investors. Wholesale revenue typically generates higher margins and lower customer acquisition costs compared to direct-to-consumer channels, directly supporting the company’s stated path toward sustainable profitability.
Key Revenue Drivers:
- Australian retail through blue-chip grocery distribution (Coles, Woolworths)
- USA Amazon expansion with multi-format product portfolio
- B2B ingredient sales to global partners seeking traceable kava extracts
The record monthly performance reflects continued improvement in channel mix and margin profile. Investors in (ASX: CCO) will be encouraged by the wholesale channel’s exceptional performance, which has already surpassed total FY25 annual results.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What Drove Calmer Co’s Record $910k Monthly Revenue?
The December sales record resulted from coordinated strength across three distinct revenue channels, each targeting different market segments and customer bases. This diversified approach reduces reliance on any single distribution channel whilst maximising total addressable market penetration.
How Is Calmer Co’s Wholesale Channel Performing in 2026?
The wholesale channel delivered breakout performance with December revenue of $340,131, marking the strongest monthly result in company history. Year-to-date wholesale sales have already exceeded total FY25 annual wholesale revenue during the first half of FY26, demonstrating accelerating momentum in B2B ingredient demand.
This performance validates global demand for high-quality, traceable kava ingredients sourced through the company’s vertically-integrated supply chain. The farm-to-shelf model provides quality assurance and supply reliability that international partners require for their own product formulations.
The wholesale channel’s acceleration is particularly significant from an investment perspective. B2B sales generate superior unit economics compared to direct-to-consumer channels, as they involve larger order volumes, predictable reorder patterns, and lower marketing expenditure per dollar of revenue. This channel mix improvement directly supports margin expansion and the trajectory toward breakeven.
Australian Retail Maintains Strong Momentum
Australian retail performance remained robust throughout December, led by established distribution of Fiji Kava® through Coles and Woolworths. These blue-chip retail partnerships provide recurring revenue from Australia’s two dominant grocery chains.
The sustained performance in major grocery retail demonstrates consumer acceptance of kava products in mainstream shopping environments. This retail footprint provides brand credibility and accessibility that extends beyond health food specialty stores into everyday grocery shopping occasions.
For investors, the Australian retail channel represents a stable revenue base with established distribution infrastructure already in place. The grocery channel generates consistent repeat purchase behaviour and builds brand awareness through in-store visibility across hundreds of locations nationally.
USA Market Expansion Through Amazon Portfolio
USA sales growth accelerated through December, driven by an expanding Amazon product range that includes tinctures, capsules, and flavoured kava shots. This multi-format strategy captures different consumer segments and usage occasions within the American market.
Amazon provides a cost-effective market entry pathway into the USA without requiring physical retail distribution agreements or extensive field sales teams. The platform’s fulfilment infrastructure and customer reach enable rapid scaling whilst maintaining lean operational overhead.
The company’s USA strategy targets the substantial existing consumer base of 21 million Americans reported to consume kava products. This established category demand reduces the need for primary consumer education and allows the company to focus on brand differentiation and product quality messaging.
Understanding Kava’s Path to Mainstream: From Traditional Use to Modern Wellness
Kava is a plant native to Pacific Island nations including Fiji, Vanuatu, and Tonga, where it has been consumed ceremonially and socially for thousands of years. The beverage, prepared from the plant’s root, is valued for its natural relaxation properties and ability to promote social connection without the cognitive impairment associated with alcohol.
In Western markets, kava has gained traction as a functional wellness product positioned at the intersection of several high-growth categories. It serves as a natural sleep aid, a relaxation supplement for stress management, and an alcohol alternative for consumers adopting mindful drinking habits.
Key Kava Attributes:
- Natural relaxation support through kavalactone compounds
- Sleep aid properties without next-day grogginess
- Alcohol alternative for social occasions
- Traditional Pacific heritage and cultural authenticity
- Non-addictive profile with established safety record when sourced from noble kava cultivars
The category’s growth potential is underpinned by convergence with broader consumer trends including the wellness movement, alcohol moderation, and demand for plant-based functional ingredients. Kava appeals to health-conscious consumers seeking effective alternatives to pharmaceutical sleep aids or alcohol consumption.
For investors, understanding kava’s dual positioning (traditional use plus modern wellness benefits) is essential to recognising the category opportunity. This is not a niche herbal supplement play but rather participation in the functional beverage, alcohol moderation, and sleep wellness categories, all experiencing strong secular growth.
Regulatory clarity is critical for mainstream adoption. Without clear compliance pathways, retail partners hesitate to stock products and digital advertising platforms restrict marketing access. The recent FDA clarification, detailed below, removes this fundamental barrier to commercial scale in the world’s largest consumer market.
What Does FDA Kava Classification Mean for Calmer Co?
The U.S. Food and Drug Administration has confirmed that traditionally prepared kava beverages qualify as food under federal law, providing landmark regulatory certainty for the category. This clarification establishes a dual-category framework that defines compliance pathways for different kava product formats sold in the American market.
Traditionally brewed kava beverages are now recognised under conventional food law, which governs items sold in grocery stores and restaurants. Other product formats, including tinctures, capsules, and flavoured kava shots, continue to sit within the dietary supplement framework regulated under the Dietary Supplement Health and Education Act.
This regulatory structure aligns directly with The Calmer Co’s multi-format portfolio strategy. The company’s product range spans both categories, enabling distribution through multiple retail channels whilst maintaining clear compliance pathways for each format.
| Product Format | Regulatory Category | Compliance Pathway | Calmer Co Portfolio Fit | Market Opportunity |
|---|---|---|---|---|
| Traditional kava beverages | Food | Conventional food law, facility registration, labelling standards | Fiji Kava® drinking powders, ready-to-drink formats | Grocery retail, food service, bars/restaurants |
| Tinctures, capsules, shots | Dietary Supplement | DSHEA framework, good manufacturing practices, supplement labelling | Amazon portfolio (tinctures, capsules, flavoured shots) | Health retailers, e-commerce, wellness channels |
| B2B ingredients | Varies by end-use | Depends on customer’s final product format | High-kavalactone extracts for global partners | Ingredient supply to manufacturers across categories |
The FDA clarification de-risks broader retail distribution by removing regulatory ambiguity that previously caused hesitation amongst mainstream retailers. Clear categorisation enables partnerships with major grocery chains, convenience stores, and food service operators who require definitive compliance guidance before stocking new product categories.
Digital advertising access also improves with regulatory certainty. Platform policies at Google, Meta, and Amazon often restrict advertising for products in undefined regulatory status. The FDA’s position provides the documentation required to appeal advertising restrictions and access performance marketing channels at scale.
For The Calmer Co, this regulatory development transforms market access potential in the USA, which represents the world’s largest consumer market with 21 million Americans already consuming kava. The clarification provides the foundation for accelerated distribution expansion, increased marketing effectiveness, and reduced execution risk in FY26 and beyond.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Investment Thesis: Path to Profitability Now Visible
The combination of record revenue performance, improving channel mix, and regulatory de-risking creates a clearer line of sight to breakeven and eventual profitability. The December result demonstrates sustainable revenue run-rate improvement rather than a one-time spike, with momentum continuing into FY26.
The wholesale channel’s acceleration is particularly significant for margin profile improvement. B2B ingredient sales typically carry superior unit economics due to larger order volumes, predictable reorder patterns, and minimal marketing expenditure requirements. As wholesale represents an increasing proportion of total revenue, the company’s path toward sustainable profitability accelerates.
The vertically-integrated farm-to-shelf model provides structural competitive advantages in margin potential and supply reliability. By controlling the supply chain from Pacific Island cultivation through to finished product, The Calmer Co captures margin at multiple points whilst ensuring quality and traceability that larger competitors struggle to replicate.
Strategic Advantages Supporting Profitability Path:
- Vertical integration from farm to finished product
- Multi-channel distribution reducing single-channel dependency
- Multi-format portfolio capturing different price points and occasions
- Regulatory clarity in USA enabling mainstream distribution
- Established blue-chip retail partnerships in Australia
The CEO’s commentary emphasises sustainable, profitable growth as the focus for FY26. The record December result, combined with wholesale channel momentum and FDA regulatory clarity, positions the company to deliver on this objective whilst expanding market presence across multiple geographies.
Want more Consumer Staples market insights?
Stay ahead with the FREE Big News Blasts from StockWire X, delivering breaking news and in-depth analysis exclusively for non-resource ASX sectors like Consumer Staples. Join over 20,000 active investors receiving timely alerts that unpack key market movements, helping informed decisions without the noise.
To get started, simply click the “Free Alerts” button at the top of the page and subscribe to StockWire X‘s expert coverage and comprehensive updates designed to keep you informed on the latest sector developments.